AMAG Ferumoxytol Avoids Safety Concerns Seen With Luitpold’s Injectafer
Executive Summary
Approval of AMAG Pharmaceuticals' anemia candidate ferumoxytol will probably not be impeded by unattributable safety issues that may resign Luitpold's Injectafer to second-line use